Scarica l'app Stockscreener
1.83
3.17%
-0.06
Dopo l'orario di chiusura:
1.81
-0.02
-1.09%
Precedente Chiudi:
$1.89
Aprire:
$1.89
Volume 24 ore:
110.35K
Relative Volume:
0.91
Capitalizzazione di mercato:
$268.62M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-8.1442
EPS:
-0.2247
Flusso di cassa netto:
-
1 W Prestazione:
-10.29%
1M Prestazione:
-1.61%
6M Prestazione:
+7.02%
1 anno Prestazione:
+0.55%
Intervallo 1D:
$1.80
$1.8945
Intervallo di 1 settimana:
$1.80
$2.08
Portata 52W:
$1.32
$2.71
Immutep Limited Adr Stock (IMMP) Company Profile
Nome
Immutep Limited Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta IMMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
1.83 | 278.19M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-17 | Iniziato | CapitalOne | Overweight |
| 2023-08-03 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-07-16 | Ripresa | Maxim Group | Buy |
| 2018-09-28 | Iniziato | B. Riley FBR | Buy |
| 2018-02-15 | Reiterato | Maxim Group | Buy |
Mostra tutto
Immutep Limited Adr Borsa (IMMP) Ultime notizie
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Immutep Limited Announces 2025 AGM with Key Resolutions - MSN
IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan
Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN
Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Reversal indicators forming on Immutep Limited Depositary Receipt stockMarket Activity Summary & Safe Entry Point Alerts - newser.com
What momentum shifts mean for Immutep Limited Depositary Receipt2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewswire Inc.
Immutep Limited Depositary Receipt Stock Lags Behind Sector BenchmarksMarket Performance Report & Weekly Setup with High ROI Potential - beatles.ru
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
12 Best Australian Stocks to Buy Right Now - Insider Monkey
Immutep Gains FDA Support for Cancer Therapy Development - TipRanks
Is Immutep Limited Depositary Receipt a good long term investmentFree Stock Market Return Analysis - PrintWeekIndia
Immutep Limited Depositary Receipt Stock Analysis and ForecastExceptional gains - jammulinksnews.com
Millennium Management LLC Sells 19,242 Shares of Immutep Limited (NASDAQ:IMMP) - Defense World
Jane Street Group LLC Has $98,000 Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Ltd Highlights Immune System Innovations at Healthcare Conference - TipRanks
Market Highlights: Immutep Limited ADR (IMMP) Ends on a Low Note at 1.93 - DWinneX
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Immutep stock soars on promising trial results - Investing.com
Immutep Quarterly Activities Report Q3 FY25 - The Manila Times
Immutep Advances Cancer Trials with Promising Developments - TipRanks
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
symbol__ Stock Quote Price and Forecast - CNN
Immutep LimitedADR (IMMP) Price Target Increased by 5.10% to 2.59 - Nasdaq
Immutep Announces Successful Meeting with the FDA on - GlobeNewswire
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - targetedonc.com
72 Biggest Movers From Friday - Benzinga
Immutep Limited Share Price ADR each Representing 10 Shares - Hargreaves Lansdown
Immutep valuation increased 16% to $510 million by Edison Investment Research - Proactive financial news
IMM Stock Price and Chart — ASX:IMM - TradingView
Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat
IMMP Stock Price and Chart — NASDAQ:IMMP - TradingView
Prima BioMed Share Price | NASDAQ IMMP Stock - Investing.com Australia
Prima BioMed Stock Price Today | NASDAQ: IMMP Live - Investing.com
Immutep Ltd Share Price | ASX IMM Stock - Investing.com Australia
Immutep Limited Adr Azioni (IMMP) Dati Finanziari
Non sono disponibili dati finanziari per Immutep Limited Adr (IMMP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):